Single‐agent ibrutinib versus chemoimmunotherapy regimens for treatment‐naïve patients with chronic lymphocytic leukemia: A cross‐trial comparison of phase 3 studies
Tadeusz Robak, Jan A. Burger, Alessandra Tedeschi et al. · American Journal of Hematology · 2018
Chemoimmunotherapy (CIT) and targeted therapy with single-agent ibrutinib are both recommended first-line treatments for chronic lymphocytic leukemia (CLL), although their outcomes have not been directly compared. Using ibrutinib data from the RESONATE-2 (PCYC-1115/1116) study conducted in patients ≥65 years without del(17p), we performed a cross-trial comparison with CIT data from published phase 3 studies in first-line treatment of CLL. Progression-free survival (PFS), overall survival (OS), and safety data for ibrutinib (median follow-up 35.7 months) were evaluated alongside available CIT data. CIT regimens included: fludarabine + cyclophosphamide + rituximab (CLL8, CLL10), bendamustine + rituximab (CLL10), obinutuzumab + chlorambucil and rituximab + chlorambucil (CLL11), and ofatumumab + chlorambucil (COMPLEMENT-1). Median age across studies was 61-74 years, with older populations receiving ibrutinib, obinutuzumab + chlorambucil, or rituximab + chlorambucil. Median follow-up varied across studies/regimens (range 14.5-37.4 months). Among all patients, PFS appeared longer with ibrutinib relative to CIT and OS appeared comparable. Relative to CIT studies that similarly excluded patients with del(17p) (CLL10) or enrolled older/less-fit patients (CLL11), PFS appeared favorable for ibrutinib in high-risk subgroups, including advanced disease, bulky lymph nodes, unmutated IGHV status, and presence of del(11q). Grade ≥ 3 infections ranged from 9% (ofatumumab + chlorambucil) to 40% (fludarabine + cyclophosphamide + rituximab), and was 25% with ibrutinib. Grade ≥ 3 neutropenia was 12% for ibrutinib and 26%-84% for CIT. Although definitive conclusions cannot be made due to inherent limitations of cross-trial comparisons, this report suggests that ibrutinib has a favorable benefit/risk profile and may potentially eliminate the need for chemotherapy in some patients. Randomized, comparative studies are needed to support these findings.
Cited by 27 works. doi:10.1002/ajh.25259 Open-access PDF
Authors
- Tadeusz Robak
- Jan A. Burger
- Alessandra Tedeschi
- Paul M. Barr
- Carolyn Owen
- Osnat Bairey
- Peter Hillmen
- David Simpson
- Sebastian Grosicki
- Stephen Devereux
- Helen O. McCarthy
- Steven E. Coutre
- Hang Quach
- Gianluca Gaïdano
- Zvenyslava Maslyak
- Don Ambrose Stevens
- Carol Moreno
- Devinder Singh Gill
- Ian W. Flinn
- John G. Gribben
References
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
- Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
- Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
- Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
- Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia
- Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial
- Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial
- Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial